All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Allogeneic stem cell transplantation (allo-SCT) is the current standard of care for patients with poor-risk acute myeloid leukemia (AML).1 Allo-SCT aims at establishing remission by exploiting the graft-versus-leukemia (GvL) effect. Nevertheless, especially in poor-risk patients, disease relapse following allo-SCT is still one of the main reasons of failure in AML.1 Thus, there is a great need for treatments that enhance the GvL effect when combined with allo-SCT, to lead to better outcomes. For this reason, Burak Kalin et al.1 investigated in the phase I/II trial, HOVON 116, the feasibility and preliminary efficacy of epigenetic therapy with panobinostat (PNB) and/or decitabine (DAC) in poor-risk AML patients. The results of this study were published in Blood Advances and are summarized below.
A total of 110 patients who were registered in the study underwent allo-SCT. The key patient baseline characteristics are shown below in Table 1. Briefly, the median age was 59 years, the majority of patients had a World Health Organization (WHO) performance status of 0–1 (83%) and a very poor HOVON/SAKK risk classification (70%)
Table 1. Patient baseline characteristics in HOVON 1161
CR, complete response; CRi, CR with incomplete hematological recovery; EVI1, ecotropic viral integration 1; FC, flow cytometry; HOVON, Dutch-Belgian Cooperative Trial Group for Hematology Oncology; MK, monosomal karyotype; MRD, measurable residual disease; PR, partial response; SAKK, Swiss Group for Clinical Cancer Research; WHO, World Health Organization |
|
Characteristic |
Patient cohort (N = 110) |
---|---|
Median age (range), years |
59 (18–71) |
Male patients, % |
61 |
WHO performance status, % 0 1 2 Unknown |
46 37 10 6 |
Response to induction Cycle 1, % CR/CRi PR Refractory |
61 7 32 |
Response to induction Cycle 2, % CR/CRi PR |
96 4 |
MRD FC (n = 74), % Positive Negative |
2 72 |
HOVON/SAKK risk group, % Poor Very poor MK EVI1 |
30 70 19 25 |
Table 2. Treatment-related toxicities by system in the HOVON 1161
DAC, decitabine; PNB, Panobinostat. |
||||
Treatment-related toxicities |
PNB monotherapy (n = 39), % |
PNB/DAC10 (n = 35), % |
||
---|---|---|---|---|
Grade 2 |
Grade 3 and above |
Grade 2 |
Grade 3 and above |
|
Blood and bone marrow |
2 |
— |
— |
— |
Gastrointestinal |
4 |
4 |
6 |
4 |
Constitutional symptoms |
4 |
2 |
— |
— |
Infections |
7 |
— |
— |
2 |
Metabolic/laboratory |
— |
4 |
— |
4 |
Eye |
2 |
— |
— |
— |
Nervous system |
— |
2 |
— |
2 |
Skin and subcutaneous tissue |
2 |
— |
— |
— |
Table 3. Efficacy outcomes from HOVON 1161
Allo-SCT, allogeneic stem cell transplantation; CIR, cumulative incidence of relapse; NRM, non-relapse mortality; OS, overall survival; PFS, progression-free survival |
|
Outcome |
Patients who underwent allo-SCT, % (N = 110) |
---|---|
2-year CIR |
35 |
2-year NRM |
16 |
2-year PFS |
49 |
2-year OS |
50 |
The results of this phase I/II trial showed that panobinostat monotherapy or in combination with 10 mg/m2 decitabine are feasible and tolerable epigenetic regimens for patients with poor-risk AML, who have undergone allo-SCT. Data did not indicate a synergistic or additive effect of panobinostat and decitabine. Due to the preliminary nature of these results, further large-scale prospective trials are needed to assess the efficacy of these post allo-SCT epigenetic therapies for the treatment of AML patients with poor outcomes.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content